<DOC>
	<DOC>NCT02926326</DOC>
	<brief_summary>An open-label, single-sequence study to evaluate the effect of azithromycin on BCT197 exposure in healthy male subjects.</brief_summary>
	<brief_title>The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers</brief_title>
	<detailed_description>This will be an open study conducted in healthy male subjects at a single centre. Each subject will participate in a screening visit and 2 study periods. At the first study period, all subjects will receive a single dose of BCT197 and at study period 2, all subjects will receive 3 daily doses of azithromycin and a single dose of BCT197.</detailed_description>
	<criteria>Inclusion Criteria Healthy male subjects. Nonsmokers (including ecigarettes). Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2. Willing to use highly effective barrier contraception methods. Male subjects must not donate sperm during the study. Exclusion Criteria Any subjects with preexisting active skin disease. Laboratory values at screening which are deemed to be clinically significant. Volunteers with abnormal liver function tests. 12 Lead ECG with QTcF &gt;450 msec. Allergy to any of BCT197 excipients. Known hypersensitivity or intolerance to azithromycin. Taking medications known to cause QTc prolongation. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Any clinically significant illness within 30 days prior to study drug administration. Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy Male volunteers</keyword>
</DOC>